Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation & Amortization (CF): 2014-2024

Historic Depreciation & Amortization (CF) for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to $1.2 million.

  • Cartesian Therapeutics' Depreciation & Amortization (CF) rose 111.89% to $606,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year increase of 202.77%. This contributed to the annual value of $1.2 million for FY2024, which is 36.54% up from last year.
  • According to the latest figures from FY2024, Cartesian Therapeutics' Depreciation & Amortization (CF) is $1.2 million, which was up 36.54% from $843,000 recorded in FY2023.
  • Cartesian Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $1.3 million during FY2022, with a 5-year trough of $734,000 in FY2020.
  • For the 3-year period, Cartesian Therapeutics' Depreciation & Amortization (CF) averaged around $1.1 million, with its median value being $1.2 million (2024).
  • As far as peak fluctuations go, Cartesian Therapeutics' Depreciation & Amortization (CF) surged by 70.57% in 2021, and later slumped by 34.50% in 2023.
  • Cartesian Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $734,000 in 2020, then surged by 70.57% to $1.3 million in 2021, then rose by 2.80% to $1.3 million in 2022, then tumbled by 34.50% to $843,000 in 2023, then spiked by 36.54% to $1.2 million in 2024.